Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013, Cancer Epidemiol, vol.53, pp.105-115, 2018. ,
Where we were, where we are, where we are going: progress in multiple myeloma, Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet, pp.199-203, 2014. ,
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study, Haematologica, 2018. ,
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study, JAMA Oncol, 2016. ,
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial, Lancet Lond Engl, vol.370, issue.9594, pp.1209-1227, 2007. ,
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.22, pp.3664-70, 2009. ,
,
, Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, vol.348, issue.19, pp.1875-83, 2003. ,
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial, Blood, vol.99, issue.3, pp.731-736, 2002. ,
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma, Blood, 1986. ,
VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma, Bone Marrow Transplant, vol.4, issue.4, pp.109-121, 1989. ,
,
Dexamethasone with Transplantation for Myeloma, N Engl J Med, vol.376, issue.14, pp.1311-1331, 201706. ,
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy, Oncol Res Treat, vol.37, issue.9, pp.506-519, 2014. ,
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses, Crit Rev Oncol Hematol, vol.113, pp.195-212, 2017. ,
Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study, Eur J Cancer Oxf Engl, vol.70, pp.22-33, 1990. ,
transplant eligible patients with multiple myeloma: a meta-analysis, Br J Haematol, vol.166, issue.5, pp.702-712, 2014. ,
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma, Blood, vol.118, issue.22, pp.5752-5758, 2011. ,
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the ,
, Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.20, pp.2475-82, 2012.
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients, BioMed Res Int, p.927105, 2015. ,
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma ,
, Blood, vol.120, issue.8, pp.1589-96, 2012.
Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma, Blood, vol.132, issue.1, p.3245, 2018. ,
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.112, issue.10, pp.4017-4040, 2008. ,
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.20, pp.2540-2547, 2013. ,
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, issue.20, pp.3073-3082, 2014. ,
Neuropathy in multiple myeloma treated with thalidomide: a prospective study, Neurology, vol.69, issue.6, pp.573-81, 2007. ,